450
Participants
Start Date
October 10, 2022
Primary Completion Date
October 9, 2030
Study Completion Date
October 9, 2030
SGLT2 inhibitor
Patients with acute decompensated HF will be open-label randomly assigned to be treated with or without SGLT2 inhibitors (either empagliflozin 10 mg once daily or dapagliflozin 10 mg once daily) 3 days before ventilator weaning in a ratio of 2:1. If the patients are allocated to SGLT2i treatment group, they will be further randomized equally to either empagliflozin- or dapagliflozin-treated group
RECRUITING
National Taiwan University Hospital, Taipei
National Taiwan University Hospital
OTHER